Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report.
Si-Man HuangTao TaoChao-Ling WanTian-Mei WuHan-Yu CaoYan QiuXiang-Dong ShenBin-Ru WangShuai-Shuai GeYan-Yan LiTong-Tong ZhangBing WuSheng-Li XuePublished in: Clinical case reports (2023)
Philadelphia chromosome-positive acute myeloid leukemia (Ph + AML) is a rare type of AML with a low survival rate and poor prognosis. We first report a Ph + AML patient who remained in long-term remission after the combination of flumatinib and venetoclax, which could provide corresponding treatment ideas for clinical practice.
Keyphrases
- acute myeloid leukemia
- poor prognosis
- acute lymphoblastic leukemia
- long non coding rna
- allogeneic hematopoietic stem cell transplantation
- clinical practice
- copy number
- chronic lymphocytic leukemia
- chronic myeloid leukemia
- case report
- disease activity
- rheumatoid arthritis
- ulcerative colitis
- dna methylation
- systemic lupus erythematosus
- genome wide